GI
BCAX

GAMMA Investing’s Bicara Therapeutics BCAX Stock Holding History

GAMMA Investing’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.5K Buy
1,465
+65
+5% +$1.45K ﹤0.01% 2394
2026
Q1 		$27.8K Buy
1,400
+275
+24% +$4.73K ﹤0.01% 2538
2025
Q4 		$18.9K Sell
1,125
-11
-1% -$188 ﹤0.01% 2649
2025
Q3 		$17.9K Buy
1,136
+459
+68% +$5.14K ﹤0.01% 2571
2025
Q2 		$6.29K Buy
677
+82
+14% +$977 ﹤0.01% 3027
2025
Q1 		$7.75K Buy
595
+536
+908% +$7.12K ﹤0.01% 2870
2024
Q4 		$1.03K Buy
+59
New +$1.23K ﹤0.01% 3418

Other funds holding BCAX

VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's BCAX Position: Q2 2026 in Review

GAMMA Investing increased its Bicara Therapeutics (BCAX) stake by 4.6% in Q2 2026, buying an estimated $1.45K and bringing the position to 1,465 shares worth $43.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

GAMMA Investing first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 5 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • GAMMA Investing held 1,465 shares of Bicara Therapeutics worth $43.5K as of Q2 2026.
  • GAMMA Investing bought 65 Bicara Therapeutics shares in Q2 2026, an estimated $1.45K.
  • Bicara Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2394 holding.
  • GAMMA Investing first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 5 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.